Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs ...

Novo Nordisk Philippines, a global healthcare company, and the Philippine College of Endocrinology, Diabetes, and Metabolism (PCEDM) have entered into a partnership agreement to address the ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...

Spending growth for simple medications used to treat common health problems is outstripping spending growth for pricey ...

a type of GLP-1 drug, was approved for chronic weight management in 2021, the Evernorth report found. GLP-1s can be quite costly: List prices for GLP-1s Wegovy and Ozempic hover around $1,000 ...